AI in clinical trials: key directions in the first half of 2026

In brief

The field is moving from generic model demos to evaluations of bounded workflow tasks.
Human–AI work may improve accuracy without saving time.
Document generation is useful as a controlled first draft, not autonomous approval.
Adaptive trials and digital twins remain promising but require prospective validation.

1. Prescreening: accuracy improved, speed did not

In a randomised retrospective evaluation of 355 records, human–AI review improved chart-level accuracy from 71.5% to 76.1%, while mean time was essentially unchanged at 37.4 versus 37.8 minutes.

The study evaluated record review—not actual enrolment. A safe system must expose criteria, sources and missing data, then leave the decision to the study team.

2. Trial matching becomes explainable

2026 work such as TrialMatchAI advances systems that retrieve registry criteria and compare them with clinical narratives.

A local reference set and explicit analysis of exclusions, unknowns and false negatives are still required before deployment.

3. Site matching moves towards readiness prediction

DocTr combines trial and site information for joint matching. Prospective evaluation on new studies is needed before operational claims.

Trialeco Site Status presents readiness, workload and risk evidence; an authorised team makes the selection.

4. AI drafts, professionals approve

Evaluations of statistical analysis plan and registry-record drafting show a practical role for AI at the first-draft stage.

Source checking, version control, role-based approval and a complete change log remain mandatory.

5. Real-time and adaptive trials

FDA has announced a real-time clinical trials proof of concept, while research explores adaptive study designs.

These are emerging infrastructures, not universal evidence of better outcomes; predetermined rules and auditable changes are essential.

6. Digital twins meet causal inference

New roadmaps connect digital twins with causal and counterfactual reasoning.

External and prospective validation, transportability analysis and explicit intended use remain prerequisites.

7. Implications for Trialeco

Trialeco is designed around bounded modules connected by Trialeco Core for integration, routing and a project action log.

The practical route is one testable workflow, synthetic public data, a local reference set and predefined stop conditions.

How to read this review

This is a thematic, not systematic, review.
The evidence includes early online publications and proofs of concept.
Metrics do not automatically transfer across diseases, countries or information systems.
A mention does not imply partnership or endorsement.